WO2001012838A3 - Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa) - Google Patents

Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa) Download PDF

Info

Publication number
WO2001012838A3
WO2001012838A3 PCT/US2000/022101 US0022101W WO0112838A3 WO 2001012838 A3 WO2001012838 A3 WO 2001012838A3 US 0022101 W US0022101 W US 0022101W WO 0112838 A3 WO0112838 A3 WO 0112838A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulate
activity
compounds
lpa receptor
lpa
Prior art date
Application number
PCT/US2000/022101
Other languages
English (en)
Other versions
WO2001012838A2 (fr
Inventor
James Erickson
J Graham Goddard
Michael Kiefer
Donald Picker
Original Assignee
Atairgin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atairgin Technologies Inc filed Critical Atairgin Technologies Inc
Priority to AU70577/00A priority Critical patent/AU7057700A/en
Publication of WO2001012838A2 publication Critical patent/WO2001012838A2/fr
Publication of WO2001012838A3 publication Critical patent/WO2001012838A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles méthodes d'identification et de caractérisation de composés modulateurs de l'activité d'un récepteur d'acide lysophosphatidique (LPA).
PCT/US2000/022101 1999-08-18 2000-08-11 Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa) WO2001012838A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70577/00A AU7057700A (en) 1999-08-18 2000-08-11 Compounds which modulate the activity of an lpa receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37639999A 1999-08-18 1999-08-18
US09/376,399 1999-08-18

Publications (2)

Publication Number Publication Date
WO2001012838A2 WO2001012838A2 (fr) 2001-02-22
WO2001012838A3 true WO2001012838A3 (fr) 2001-10-04

Family

ID=23484875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022101 WO2001012838A2 (fr) 1999-08-18 2000-08-11 Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa)

Country Status (2)

Country Link
AU (1) AU7057700A (fr)
WO (1) WO2001012838A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
AU2003278165A1 (en) * 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human endothelial differentiation, lysophosphatidic acid g-protein-coupled receptor 2 (edg2)
EP2428211A4 (fr) * 2009-05-07 2013-04-03 Moon & J Inc Composition pharmaceutique pour prévenir ou traiter une lésion neuronale ou des maladies neurologiques
CN104066729A (zh) 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5176423A (ja) * 1974-12-26 1976-07-02 Kao Corp Hiiryoyokokinzai
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
EP0747047A1 (fr) * 1995-05-17 1996-12-11 LA ROCHE POSAY Laboratoire Pharmaceutique Association d'un composé à activité anti-microbienne (e.g. du lipoaminoacide N,n-Octanoyl-glycine) et d'un monoalkyléther de glycérol et son usage en tant d'agent anti-microbien
WO1998041213A1 (fr) * 1997-03-19 1998-09-24 Lxr Biotechnology Inc. Compositions contenant des acides lysophosphotidiques inhibant l'apoptose, et leurs utilisations
WO1999008514A1 (fr) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions contenant du polyethylene glycol et leurs utilisations
WO1999019513A2 (fr) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Procedes pour la detection de composes modulant l'activite d'un recepteur d'acide lysophosphatidique (lpa)
WO1999047101A2 (fr) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions contenant des acides lysophosphatidiques qui inhibent l'apoptose et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5176423A (ja) * 1974-12-26 1976-07-02 Kao Corp Hiiryoyokokinzai
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
US5480877A (en) * 1993-11-02 1996-01-02 Wisconsin Alumni Research Foundation Use of lysophosphatidic acids to enhance fibronectin binding
EP0747047A1 (fr) * 1995-05-17 1996-12-11 LA ROCHE POSAY Laboratoire Pharmaceutique Association d'un composé à activité anti-microbienne (e.g. du lipoaminoacide N,n-Octanoyl-glycine) et d'un monoalkyléther de glycérol et son usage en tant d'agent anti-microbien
WO1998041213A1 (fr) * 1997-03-19 1998-09-24 Lxr Biotechnology Inc. Compositions contenant des acides lysophosphotidiques inhibant l'apoptose, et leurs utilisations
WO1999008514A1 (fr) * 1997-08-20 1999-02-25 Lxr Biotechnology, Inc. Compositions contenant du polyethylene glycol et leurs utilisations
WO1999019513A2 (fr) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Procedes pour la detection de composes modulant l'activite d'un recepteur d'acide lysophosphatidique (lpa)
WO1999047101A2 (fr) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions contenant des acides lysophosphatidiques qui inhibent l'apoptose et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDO K ET AL: "ANTITUMOR ACTIVITY OF GLYCERYL ETHERS", CANCER RESEARCH,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 32, January 1972 (1972-01-01), pages 125 - 129, XP000944227, ISSN: 0008-5472 *
BANDOH, K. ET AL: "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors", FEBS LETT. (2000), 478(1,2), 159-165, XP000990176 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIZAWA, KAZUNORI ET AL: "Alkoxyalkanol antimicrobial agents", XP002164099, retrieved from STN Database accession no. 85:159409 *
ERICKSON J R ET AL: "EDG-2/VZG-1 COUPLES TO THE YEAST PHEROMONE RESPONSE PATHWAY SELECTIVELY IN RESPONSE TO LYSOPHOSPHATIDIC ACID", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 3, 16 January 1998 (1998-01-16), pages 1506 - 1510, XP000783622, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU7057700A (en) 2001-03-13
WO2001012838A2 (fr) 2001-02-22

Similar Documents

Publication Publication Date Title
WO1999019513A3 (fr) Procedes pour la detection de composes modulant l'activite d'un recepteur d'acide lysophosphatidique (lpa)
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
AU4677699A (en) Methods for identifying novel multimeric agents that modulate receptors
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
AU4674599A (en) Novel therapeutic agents that modulate enzymatic processes
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
AU1623200A (en) Method for identifying the language of individual words
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
AU2003265859A1 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
DK0984665T3 (da) Transducer til delvis eller fuldstændig implanterbart höreapparat
ZA200201518B (en) Dispersion formulations containing lipase inhibitors.
WO1999025843A3 (fr) Kinase humaine de controle, hcds1, compositions et procedes
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
ZA985026B (en) Method for enhancing the activity of an enzyme.
AU4158797A (en) Screening assay for the identification of agents which alter expression of pth-rp
AU2001226387A1 (en) Methods of identifying modulators of the fgf receptor
AU6748000A (en) Method for identifying compounds which modulate circadian rhythm
WO2001059153A3 (fr) Procede d'identification de substances qui modulent l'activite de canaux de cations actives par hypolarisation
WO2001012838A3 (fr) Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa)
ZA988025B (en) Method for enhancing the activity of an enzyme.
MXPA01008214A (es) Inhibidores de separina, metodo para identificarlos y usos.
WO2001020335A3 (fr) Procedes de modulation de la proliferation cellulaire
WO2000036101A3 (fr) Proteine de cassette de liaison a l'atp responsable de la resistance aux cytotoxines
AU1971200A (en) Assays for compounds which increase phospholipase a2 activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP